Characterizing patient preferences and personalizing risk information for optimal patient-centered management of coronary artery disease (OPCM-CAD)


The purpose of this research study is to help doctors and other clinicians understand patient preferences about the different treatment options (open-heart surgery, balloon stenting, and medication) for managing coronary artery disease (CAD). This study also hopes to develop tools that can be used to explain the personalized risk of different treatment options to CAD patients in the context of shared-decision making.

The three objectives are:

  1. Characterize patient preferences toward CAD treatments via a discrete choice experiment (DCE).
  2. Develop and validate models to predict individualized patient risks of mortality, readmissions for myocardial infarction (MI), unplanned revascularization, stroke, and kidney failure under different treatment strategies.
  3. Estimate net effects of the treatment options based on trade-offs in patient-important risks and benefits for adverse outcomes of patients to better understand when benefits of revascularization exceed risk for individual patients.

Given the increasing complexity of CAD management, new clinical decision support tools are needed to aid risk stratification and communication of personalized risk information to support the clinical decision-making process about the selection of appropriate treatment strategies for each patient. We hope to improve patient engagement and satisfaction, and ensure delivery of the treatments that are most likely to benefit patients and align with their values and preferences.

We will do this by delivering a patient co-developed questionnaire, called a DCE, to 400 diverse participants with lived experience of CAD. This questionnaire will collect participant’s sociodemographic data and disease characteristics, and will then describe hypothetical scenarios in which participants will choose between various CAD treatment options based on the personalized risk of each treatment. This will elicit patient preferences towards the different treatment options available for managing CAD. We also plan to develop and validate models that predict individual patient risks of potential treatment outcomes. Lastly, we hope to integrate the results of the first two objectives to determine net effects associated with the various treatment options for each patient.

Roles and Responsibilities

We hope to include up to three patient partners with either lived experience of CAD or heart disease to join our study steering committee. In this committee, patient partners would share essential insights and feedback on the design and implementation of the discreet choice experiment (including survey development), presentation of study results (benefits and risks of each treatment strategy), and knowledge translation activities related to this project. Our hope is to have a patient advisory group that is representative of the diverse communities and populations that make up Alberta.

Our end-of-grant dissemination activities will include sharing project findings with patient advisors and DCE participants, and target provincial and (inter)national audiences, for example Alberta Health Services Cardiovascular Health and Stroke Strategic Clinical Network (AHS-SCN), Canadian Cardiovascular Congress, and American Heart Association.

Time Commitment

This project is anticipated to start on June 1st, 2023, and continue for 4 years. As members of the steering committee, patient partners will be expected to attend steering committee meetings approximately every 2 months as well as any additional meetings requiring their attendance. These meetings will be virtual and last about an hour. There will be no more than 12 meetings per year.


Compensation will be offered as per AbSPORU Patient Partner Compensation Guidelines. This is an online opportunity so there are no direct expenses such as travel, parking, etc. associated with engagement.

Dr. Tolulope Sajobi
Nirav Bhagat

Stay connected with AbSPORU and our research by signing up for our emails.


University of Calgary Foothills Campus
3330 Hospital Dr NW
Calgary, AB T2N 4N1


College Plaza
1702, 8215 112 St NW
Edmonton, AB T6G 2C8

Land Acknowledgment

The Alberta SPOR SUPPORT Unit operates on and acknowledges the lands that are the traditional and ancestral territory of many peoples, presently subject to Treaties 6, 7, and 8. Namely: the Blackfoot Confederacy – Kainai, Piikani, and Siksika – the Cree, Dene, Saulteaux, Nakota Sioux, Stoney Nakoda, and the Tsuu T’ina Nation and the Métis People of Alberta. This includes the Métis Settlements and the Métis Nation of Alberta. We acknowledge the many First Nations, Métis and Inuit who have lived in and cared for these lands for generations. We make this acknowledgment as a reaffirmation of our shared commitment towards reconciliation, and as part of AbSPORU’s mandate towards fostering health system transformation.